Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).
Company Details
- Employees
- 22
- Founded
- -
- Address
- 1000 Marina Blvd, Brisbane,california 94005,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.nitrasetx.com
- HQ
- Brisbane, California
Nitrase Therapeutics Questions
Nitrase Therapeutics's website is http://www.nitrasetx.com
Nitrase Therapeutics's LinkedIn profile is https://www.linkedin.com/company/nitrase-therapeutics
Nitrase Therapeutics has
22 employees.
View email and phone details for 22
employees at Nitrase Therapeutics.
Nitrase Therapeutics's industry is
Biotechnology Research
Nitrase Therapeutics's top competitors are
Lyterian Therapeutics,
Fountain Therapeutics,
Labops Unite Community,
Soteria Biotherapeutics,
Pendulum Therapeutics,
Vicinitas Therapeutics,
Mediar Therapeutics,
Lycia Therapeutics,
Grace Science, Llc,
Montara Therapeutics, Inc..
Nitrase Therapeutics's categories are Biotechnology Research
Nitrase Therapeutics's founding year is 2018
